Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed
Agreements In 2012 And 2013 Alleged To Have Delayed Competition Until 2021
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.
